EGFR and non-small cell lung carcinoma: The ongoing SOUND Clinical Trial (NCT05374603) is an open-label, multicenter, exploratory clinical trial that aims to investigate the combination therapy of savolitinib and durvalumab in Chinese patients with EGFR wild-type topical or metastatic NSCLC who have MET mutations.